LA
EGRX

Legacy Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Legacy Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,800
Closed -$94K – 461
2018
Q1 		$94K Buy
+1,800
New +$105K 0.07% 120

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Legacy Advisors's EGRX Position: Q2 2018 in Review

Legacy Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2018, closing a stake of 1,800 shares — an estimated $94K sold.

Legacy Advisors first reported a position in EGRX in Q1 2018 and held it in 1 quarter. The position peaked at $94K in Q1 2018. 183 funds tracked by Wall St. Rank hold EGRX as of Q2 2018.

  • Legacy Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Legacy Advisors sold 1,800 Eagle Pharmaceuticals, Inc. shares in Q2 2018, an estimated $94K.
  • Legacy Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Legacy Advisors's Eagle Pharmaceuticals, Inc. position peaked at $94K in Q1 2018.
  • 183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2018.

Based on Legacy Advisors's 13F filing for Q2 2018, filed 19 Jul 2018.